If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
=== Observational evidence === In 2015, a study of galactic mid-infrared emissions concluded that "Kardashev Type III civilizations are either very rare or do not exist in the local Universe". In 2016, Paul Gilster, author of the Centauri Dreams website, described a signal apparently coming from the star HD 164595 as requiring the power of a Type I or Type II civilization, if produced by extraterrestrial lifeforms. In August 2016, however, it was discovered that the origin of the signal was most likely a military satellite orbiting the Earth.
His work has emphasized the use of gene expression profiling and genomic analysis to improve diagnostic accuracy and distinguish between histologically similar tumors, including synovial sarcoma and other spindle cell neoplasms. Nielsen's studies have also examined the role of characteristic fusion oncogenes, such as SS18–SSX in synovial sarcoma, and their effects on gene regulation and tumor development. This research has helped clarify the biological mechanisms underlying sarcoma progression and supported the development of molecularly defined disease categories.
=== Nuclear fission === Einsteinium has a high rate of nuclear fission that results in a low critical mass. This mass is 9.89 kilograms for a bare sphere of 254Es, and can be lowered to 2.9 kg by adding a 30-centimeter-thick steel neutron reflector, or even to 2.26 kg with a 20-cm-thick reflector made of water. However, even this small critical mass far exceeds the total amount of einsteinium isolated so far, especially of the rare 254Es.
== Construction of the Cologne mosque (2007) == On June 4, 2007, Kermani published a report in the Süddeutsche Zeitung about a public hearing on the construction of a mosque in the district of Cologne-Ehrenfeld. In the report, Kermani expressed enthusiasm for the open atmosphere of discussion. Attesting that the citizens present embodied "democracy in its purest form", Kermani noted that there is a "broad, cosmopolitan middle" in Cologne whose members are far more tolerant than many intellectuals.
The energy given off during either nuclear fusion or nuclear fission is the difference of the binding energies of the "fuel", i.e. the initial nuclide(s), from that of the fission or fusion products. In practice, this energy may also be calculated from the substantial mass differences between the fuel and products, which uses previous measurements of the atomic masses of known nuclides, which always have the same mass for each species. This mass difference appears once evolved heat and radiation have been removed, which is required for measuring the (rest) masses of the (non-excited) nuclides involved in such calculations.
Sources: en.wikipedia.org
The grant was intended to support research into the interactions of hydrogen with palladium, nickel or platinum under extreme conditions. In March 2013 Graham K. Hubler, a nuclear physicist who worked for the Naval Research Laboratory for 40 years, was named director. One of the SKINR projects is to replicate a 1991 experiment in which a professor associated with the project, Mark Prelas, says bursts of millions of neutrons a second were recorded, which was stopped because "his research account had been frozen". He claims that the new experiment has already seen "neutron emissions at similar levels to the 1991 observation". In May 2016, the United States House Committee on Armed Services, in its report on the 2017 National Defense Authorization Act, directed the Secretary of Defense to "provide a briefing on the military utility of recent U.S. industrial base LENR advancements to the House Committee on Armed Services by September 22, 2016".
=== Quality, digestibility and energy density === There are a few key components to consider when evaluating dietary needs. These factors include the quality and digestibility of the protein provided in the diet, as well as the composition of the amino acids included, and finally the energy density provided in the diet. Diets containing proteins that are high in quality, composition, and digestibility require less of that protein to be present. The same can be said in regards to the energy density. In contrast, high-protein diets will provide excess protein content after meeting maintenance demands; this can therefore lead to the protein being utilized in fat and energy storage. This ultimately increases the risk for developing obesity and other health related issues. Higher protein in the diet helps reduce lean body mass loss, but will not lead to an increase in size of muscle unless paired with resistance exercises or anabolic steroids under maintenance conditions.
== Brigade Commanders == 2003 - 2005 : Général Jean-Paul Thonier 2005 - 2007 : Général Hervé Charpentier 2007 - 2009 : Général Éric Bonnemaison 2009 - 2011 : Général Jean-François Hogard 2011 - 2013 : Général François Lecointre 2013 - 2015 : Général Vincent Guionie 2015 - 201x :: Général François Labuze
restriction mapping The use of type II restriction endonucleases to cleave DNA molecules at specific restriction sites in order to produce characteristic patterns of fragments which can be resolved by size using gel electrophoresis. Digesting DNA molecules such as genomic DNA or plasmids with one or multiple restriction enzymes makes it possible to deduce from the sizes of the resulting fragments the order or arrangement of the restriction sites within the molecule and the distances between them, and thus to construct reliable maps with restriction sites effectively serving as genetic markers.
Multi-walled nanotubes (MWNTs) consist of multiple rolled layers (concentric tubes) of graphene. There are two models that can be used to describe the structures of multi-walled nanotubes. In the Russian Doll model, sheets of graphite are arranged in concentric cylinders, e.g., a (0,8) single-walled nanotube (SWNT) within a larger (0,17) single-walled nanotube. In the Parchment model, a single sheet of graphite is rolled in around itself, resembling a scroll of parchment or a rolled newspaper. The interlayer distance in multi-walled nanotubes is close to the distance between graphene layers in graphite, approximately 3.4 Å. The Russian Doll structure is observed more commonly. Its individual shells can be described as SWNTs, which can be metallic or semiconducting. Because of statistical probability and restrictions on the relative diameters of the individual tubes, one of the shells, and thus the whole MWNT, is usually a zero-gap metal. Double-walled carbon nanotubes (DWNTs) form a special class of nanotubes because their morphology and properties are similar to those of SWNTs but they are more resistant to attacks by chemicals. This is especially important when it is necessary to graft chemical functions to the surface of the nanotubes (functionalization) to add properties to the CNT. Covalent functionalization of SWNTs will break some C=C double bonds, leaving "holes" in the structure on the nanotube and thus modifying both its mechanical and electrical properties. In the case of DWNTs, only the outer wall is modified.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.